Personalis, Inc. (NASDAQ:PSNL) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lessened its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 83.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,686 shares of the company's stock after selling 131,553 shares during the quarter. Cubist Systematic Strategies LLC's holdings in Personalis were worth $148,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. abrdn plc acquired a new stake in Personalis in the 4th quarter worth about $1,722,000. Dimensional Fund Advisors LP increased its stake in shares of Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock valued at $2,372,000 after acquiring an additional 242,141 shares during the last quarter. Barclays PLC lifted its holdings in shares of Personalis by 67.1% during the 4th quarter. Barclays PLC now owns 109,368 shares of the company's stock worth $632,000 after acquiring an additional 43,900 shares during the period. Jane Street Group LLC boosted its position in shares of Personalis by 144.3% in the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock worth $2,320,000 after acquiring an additional 237,033 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Personalis in the fourth quarter worth approximately $64,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PSNL. Craig Hallum began coverage on Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 price objective for the company. HC Wainwright upped their price target on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and issued a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Finally, Guggenheim assumed coverage on Personalis in a report on Thursday, May 15th. They set a "buy" rating and a $6.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $7.67.

Personalis Stock Performance

Shares of NASDAQ:PSNL traded down $0.10 during mid-day trading on Thursday, hitting $4.62. 434,228 shares of the company traded hands, compared to its average volume of 1,009,295. The firm's 50 day simple moving average is $3.84 and its 200 day simple moving average is $4.46. The firm has a market cap of $408.06 million, a P/E ratio of -2.75 and a beta of 1.83. Personalis, Inc. has a 52-week low of $1.14 and a 52-week high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The business had revenue of $20.61 million for the quarter, compared to analysts' expectations of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Equities research analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.